Edition:
United States

Radius Health Inc (RDUS.OQ)

RDUS.OQ on NASDAQ Stock Exchange Global Market

17.93USD
21 Sep 2018
Change (% chg)

$-0.90 (-4.78%)
Prev Close
$18.83
Open
$18.82
Day's High
$18.98
Day's Low
$17.82
Volume
970,292
Avg. Vol
255,521
52-wk High
$41.14
52-wk Low
$16.71

Latest Key Developments (Source: Significant Developments)

Radius Health Provides Update On CHMP Opinion For Abaloparatide-SC
Thursday, 22 Mar 2018 09:00am EDT 

March 22 (Reuters) - Radius Health Inc ::RADIUS HEALTH PROVIDES UPDATE ON CHMP OPINION FOR ABALOPARATIDE-SC.RADIUS HEALTH INC - EMA INFORMED CO THAT CHMP WILL ADOPT A NEGATIVE OPINION ON MAA ON THURSDAY.RADIUS HEALTH - INTENDS TO APPEAL AND IMMEDIATELY SEEK A RE-EXAMINATION OF CHMP OPINION.RADIUS HEALTH INC - ‍CHMP COMMUNICATED A NEGATIVE TREND VOTE ON BENEFIT-RISK BALANCE FOR CO'S MARKETING AUTHORIZATION APPLICATION FOR ABALOPARATIDE-SC​.  Full Article

Radius Health Entered Scale-Up And Commercial Supply Agreement With 3M
Friday, 2 Mar 2018 05:02pm EST 

March 2 (Reuters) - 3M Co ::RADIUS HEALTH SAYS ON FEB 27, ENTERED INTO SCALE-UP AND COMMERCIAL SUPPLY AGREEMENT WITH 3M CO AND 3M INNOVATIVE PROPERTIES CO - SEC FILING.RADIUS HEALTH - PER SUPPLY AGREEMENT, 3M TO MANUFACTURE PHASE 3 & GLOBAL COMMERCIAL SUPPLIES OF AN ABALOPARATIDE-COATED TRANSDERMAL PATCH PRODUCT FOR CO.RADIUS HEALTH INC SAYS CO AND 3M PREVIOUSLY ENTERED INTO A DEVELOPMENT AND CLINICAL SUPPLIES AGREEMENT DATED JUNE 19, 2009.RADIUS HEALTH - ON FEB 27, CO ENTERED INTO SIXTH AMENDMENT TO JUNE 2009 DEVELOPMENT AGREEMENT TO EXTEND INITIAL TERM OF AGREEMENT UNTIL JUNE 19, 2019.  Full Article

Radius Health Reports Q4 Loss Per Share $1.59
Thursday, 1 Mar 2018 04:01pm EST 

March 1 (Reuters) - Radius Health Inc ::RADIUS HEALTH REPORTS FOURTH QUARTER AND FULL YEAR 2017 FINANCIAL AND OPERATING RESULTS AND PROVIDES BUSINESS UPDATE.Q4 LOSS PER SHARE $1.59.Q4 EARNINGS PER SHARE VIEW $-1.43 -- THOMSON REUTERS I/B/E/S.  Full Article

Radius Health Expects CHMP To Issue Opinion Regarding Marketing Authorization Application Of Abaloparatide-Sc during H1 2018
Friday, 15 Dec 2017 07:31am EST 

Dec 15 (Reuters) - Radius Health Inc ::RADIUS HEALTH ANNOUNCES THAT THE COMMITTEE FOR MEDICINAL PRODUCTS FOR HUMAN USE (CHMP) WILL ISSUE A THIRD DAY-180 LIST OF OUTSTANDING ISSUES IN ITS REGULATORY REVIEW OF ABALOPARATIDE-SC, A BONE BUILDING AGENT FOR THE TREATMENT OF OSTEOPOROSIS IN POSTMENOPAUSAL WOMEN AT INCREASED RISK OF FRACTURE.RADIUS HEALTH-EXPECTS COMMITTEE FOR MEDICINAL PRODUCTS FOR HUMAN USE TO ISSUE AN OPINION REGARDING MARKETING AUTHORISATION APPLICATION DURING H1 2018.  Full Article

Radius Health reports Q3 loss per share $1.31
Thursday, 2 Nov 2017 04:01pm EDT 

Nov 2 (Reuters) - Radius Health Inc :Radius Health Inc reports third quarter 2017 financial and operating results and provides business update.Q3 loss per share $1.31.Q3 earnings per share view $-1.26 -- Thomson Reuters I/B/E/S.Radius Health Inc - ‍expects to submit a labeling supplement to FDA in connection with activextend results by end of 2017​.Radius health inc - ‍expects to reduce size of board from 10 to 9 members​.Radius Health Inc - believe have sufficient capital to fund development plans, U.S. Commercial and other operational activities for not less than 12 months​.  Full Article

Radius Health receives FDA fast track designation for elacestrant
Wednesday, 18 Oct 2017 09:00am EDT 

Oct 18 (Reuters) - Radius Health Inc :Radius health receives fda fast track designation for elacestrant (rad1901).Radius health - ‍plans to initiate phase 2 clinical study of elacestrant as a third-line therapy for women with er+ and her2- breast cancer early in 2018​.Radius health inc - ‍expect to enroll first patient in phase 2 study in early 2018​.  Full Article

Radius Health initiates Phase 1 clinical trial of RAD140 for treatment of hormone receptor positive breast cancer
Friday, 29 Sep 2017 08:45am EDT 

Sept 29 (Reuters) - Radius Health Inc :Radius Health initiates Phase 1 clinical trial of RAD140 for the treatment of hormone receptor positive breast cancer.Radius Health Inc - ‍clinical trial is designed to evaluate safety and maximum tolerated dose of RAD140 in approximately 40 patients​.Radius Health Inc - pharmacokinetics, pharmacodynamics and tumor response will also be evaluated in Phase 1 trial​.  Full Article

Radius Health prices $300 mln of 3 pct convertible senior notes due 2024
Tuesday, 8 Aug 2017 11:16pm EDT 

Aug 8 (Reuters) - Radius Health Inc :Radius Health announces pricing of $300 million of 3.00 percent convertible senior notes due 2024.Notes will pay interest semi-annually in arrears on March 1 and September 1 of each year at rate of 3.00 percent per year.Estimates that net proceeds from offering of notes will be approximately $290.8 million.  Full Article

Radius Health announces proposed public offering of $300 million of convertible senior notes due 2024
Monday, 7 Aug 2017 04:22pm EDT 

Aug 7 (Reuters) - Radius Health Inc :Radius Health - to use net proceeds to support U.S. commercial launch of Tymlos injection, development of its life cycle management activities​.  Full Article

Radius Health reports Q2 loss per share $1.58
Thursday, 3 Aug 2017 04:01pm EDT 

Aug 3 (Reuters) - Radius Health Inc :Radius Health reports second quarter 2017 financial and operating results and provides business update.Q2 loss per share $1.58.Q2 earnings per share view $-1.23 -- Thomson Reuters I/B/E/S.  Full Article

BRIEF-Radius Health Reports Q1 Loss Per Share Of $1.37

* RADIUS HEALTH REPORTS FIRST QUARTER 2018 FINANCIAL AND OPERATING RESULTS AND PROVIDES BUSINESS UPDATE